Cagrilintide: Long-Acting Amylin Analog Research, CagriSema & Weight Management

Written by NorthPeptide Research Team

For laboratory and research use only. Not for human consumption.

Cagrilintide represents a distinct approach in metabolic peptide research. Rather than targeting the incretin pathway shared by GLP-1 and GIP receptor agonists, cagrilintide activates the amylin receptor system — a complementary signaling axis that has attracted significant research attention for its role in energy balance and glycemic regulation. Developed by Novo Nordisk, this long-acting amylin analog has progressed through Phase 2 trials as a monotherapy and is currently in Phase 3 development as part of the CagriSema combination. This guide provides a comprehensive overview of cagrilintide’s molecular design, mechanism of action, published clinical data, and its position within the evolving landscape of metabolic peptide research.

What Is Cagrilintide?

Cagrilintide (formerly designated NN9838 and AM833) is a synthetic, long-acting analog of human amylin, a 37-amino-acid peptide hormone that is naturally co-secreted with insulin from pancreatic beta cells in response to nutrient intake. Native amylin plays a well-documented role in postprandial glucose regulation and satiety signaling, but its therapeutic application has been limited by its extremely short circulating half-life (approximately 13 minutes) and its tendency to aggregate and form amyloid fibrils at higher concentrations.

Novo Nordisk engineered cagrilintide to overcome these pharmacological limitations through two key structural modifications:

• Acylation with a C18 fatty diacid — A lipid side chain is conjugated to the peptide backbone, enabling reversible, non-covalent binding to serum albumin. This albumin binding dramatically extends the circulating half-life from minutes to approximately 7 days, making once-weekly subcutaneous administration feasible in research protocols.
• Amino acid substitutions for stability — Targeted modifications to the native amylin sequence reduce the peptide’s propensity for aggregation and amyloid fibril formation, a critical safety consideration that limited the clinical utility of earlier amylin-based compounds such as pramlintide (Symlin), which requires multiple daily injections due to its short duration of action.

The result is a peptide that retains the receptor pharmacology of native amylin while offering a dramatically improved pharmacokinetic profile suitable for once-weekly dosing — a significant advancement over pramlintide’s three-times-daily injection schedule.

Mechanism of Action: Amylin Receptor Biology

To understand how cagrilintide works, it is necessary to examine the amylin receptor system in detail. Unlike the relatively straightforward receptor pharmacology of GLP-1 agonists (which bind a single receptor), amylin signaling involves a more complex receptor architecture that has been the subject of extensive molecular pharmacology research.

Amylin Receptor Architecture

Amylin receptors are not standalone proteins. Instead, they are heterodimeric complexes formed by the pairing of the calcitonin receptor (CTR) with one of three receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3). Each combination produces a distinct receptor subtype with different pharmacological properties:

• AMY1 receptor — CTR + RAMP1: The primary amylin receptor subtype, with the highest affinity for native amylin. Densely expressed in the area postrema, nucleus accumbens, and dorsal vagal complex.
• AMY2 receptor — CTR + RAMP2: Expressed in brain regions involved in feeding behavior and metabolic regulation. Research suggests involvement in long-term energy balance signaling.
• AMY3 receptor — CTR + RAMP3: The most broadly distributed subtype, found in brain, kidney, and peripheral tissues. This subtype has been associated with both metabolic and cardiovascular signaling in preclinical models.

Cagrilintide activates all three amylin receptor subtypes (AMY1, AMY2, and AMY3), as well as the calcitonin receptor itself. This broad receptor engagement profile distinguishes it from native amylin, which preferentially activates AMY1 and AMY3, and from pramlintide, which has a more limited receptor activation pattern.

Downstream Signaling and Physiological Effects

Activation of amylin receptors by cagrilintide triggers several interconnected downstream effects that have been characterized in preclinical and clinical research:

• Satiety signaling via the area postrema and brainstem — The area postrema, a circumventricular organ located in the brainstem, is the primary site of amylin’s appetite-suppressing effects. Unlike hypothalamic satiety centers, the area postrema lacks a complete blood-brain barrier, allowing circulating amylin analogs direct access to these neurons. Amylin receptor activation in this region has been shown to reduce meal size and increase meal-to-meal intervals in preclinical models.
• Delayed gastric emptying — Amylin receptor signaling reduces the rate at which the stomach empties its contents into the duodenum. This slowing of gastric transit is mediated via vagal afferent pathways and contributes to prolonged postprandial satiety. The effect is dose-dependent and has been consistently observed across amylin analog studies.
• Suppression of postprandial glucagon secretion — Amylin acts on pancreatic alpha cells to reduce glucagon release following meals. Since glucagon stimulates hepatic glucose production, this suppression contributes to improved postprandial glucose regulation. Importantly, this glucagon-suppressing effect is glucose-dependent — it does not impair the counter-regulatory glucagon response to hypoglycemia, a critical safety characteristic observed in research.
• Modulation of reward-related feeding behavior — Emerging preclinical research has suggested that amylin receptor signaling may influence mesolimbic dopaminergic pathways involved in the hedonic (reward-driven) aspects of food intake, distinct from the homeostatic satiety signals mediated by the area postrema. This dual mechanism — targeting both homeostatic and hedonic feeding circuits — has been hypothesized as one reason amylin pathway activation may complement GLP-1-based approaches.

Why the Amylin Pathway Is Complementary to GLP-1

A critical concept in current metabolic peptide research is that amylin and GLP-1 act through fundamentally different — and non-redundant — signaling pathways. GLP-1 receptor agonists primarily act on hypothalamic appetite centers, pancreatic beta cells (insulin secretion), and the gastrointestinal tract. Amylin receptor agonists primarily act on the area postrema and brainstem circuits, with additional effects on gastric emptying and glucagon secretion.

Research has demonstrated that combining these two pathways produces additive or potentially synergistic effects on body weight reduction that exceed what either pathway achieves alone. This complementarity forms the scientific rationale for the CagriSema combination program, discussed in detail below.

Research Applications Under Investigation

Cagrilintide is being investigated across several research domains, reflecting the broad physiological role of the amylin signaling system:

• Body weight regulation — The primary research focus, with Phase 2 monotherapy data and Phase 3 combination data (CagriSema) demonstrating significant body weight reduction in clinical trial populations.
• Glycemic control and type 2 diabetes — Given amylin’s established role in postprandial glucose regulation, cagrilintide is being investigated for its effects on HbA1c and glycemic variability, both as monotherapy and in combination with semaglutide.
• Combination pharmacology — The CagriSema program represents a broader research interest in multi-pathway approaches to metabolic regulation, testing the hypothesis that targeting complementary receptor systems produces superior outcomes compared to single-pathway maximization.
• Amylin receptor biology — Cagrilintide serves as a pharmacological tool for studying the amylin receptor system, including receptor subtype selectivity, RAMP biology, and the distinction between calcitonin and amylin receptor-mediated effects.
• Neurobiological feeding circuits — Research into cagrilintide’s effects on brainstem versus hypothalamic satiety signaling contributes to a broader understanding of how different hormonal pathways regulate energy intake and body weight.

Clinical Trial Data

Cagrilintide has been the subject of a structured clinical development program, with published data from Phase 1 and Phase 2 trials and ongoing Phase 3 investigations.

Phase 2 Monotherapy Trial

The pivotal Phase 2 trial for cagrilintide monotherapy was a randomized, double-blind, placebo-controlled study evaluating multiple dose levels administered subcutaneously once weekly in adults with overweight or obesity. Key findings from this 26-week trial included:

• Body weight reduction of approximately 10-11% at the highest doses studied, compared to approximately 3% in the placebo group. This dose-dependent weight loss was statistically significant across the active treatment arms.
• Dose-response relationship — A clear dose-response curve was observed, with higher doses producing greater body weight reductions, supporting the pharmacological relationship between amylin receptor activation and weight outcomes.
• Tolerability profile — The most common adverse events were gastrointestinal in nature, primarily nausea, which was most pronounced during the initial weeks of treatment and attenuated with continued dosing.
• Sustained effect through 26 weeks — Body weight continued to decline throughout the study period without evidence of a plateau at the higher doses, suggesting that longer treatment durations might yield additional reductions.

These Phase 2 monotherapy results established that long-acting amylin receptor agonism alone could produce clinically meaningful body weight reduction, confirming the biological significance of this pathway and providing the rationale for combination studies.

CagriSema Combination: Phase 2 Data

The most closely watched data in cagrilintide’s development comes from the CagriSema program — the co-administration of cagrilintide with semaglutide 2.4 mg (the GLP-1 receptor agonist marketed as Wegovy). This combination was designed to simultaneously activate the amylin and GLP-1 receptor systems, testing the hypothesis that pathway complementarity translates to superior clinical outcomes.

Phase 2 results for CagriSema demonstrated:

• Body weight reduction of approximately 22-24% at the highest combination doses over the study period — substantially exceeding the ~15-17% typically observed with semaglutide 2.4 mg monotherapy in comparable populations, and the ~10-11% observed with cagrilintide monotherapy.
• Apparent additive effect — The magnitude of weight reduction with the combination approximated the sum of the individual monotherapy effects, consistent with the hypothesis of non-redundant, complementary mechanisms.
• Glycemic improvements — In subjects with type 2 diabetes, CagriSema was associated with significant reductions in HbA1c, reflecting the combined insulin-sensitizing and glucagon-suppressing effects of the two pathways.

These results positioned CagriSema as one of the most efficacious investigational approaches in metabolic peptide research and led directly to the initiation of a comprehensive Phase 3 program.

Phase 3 Program (Ongoing)

Novo Nordisk has initiated a large-scale Phase 3 program for CagriSema, comprising multiple trials across different populations and endpoints. As of early 2026, key trials include:

• REDEFINE 1 — CagriSema in adults with obesity without diabetes, with co-primary endpoints of body weight reduction and proportion achieving clinically meaningful weight loss thresholds.
• REDEFINE 2 — CagriSema in adults with obesity and type 2 diabetes, evaluating both weight and glycemic endpoints.
• Additional REDEFINE studies — Evaluating maintenance of weight loss, cardiovascular outcomes, and effects in specific populations.

Regulatory submission for CagriSema is anticipated pending completion and analysis of the Phase 3 program. Neither cagrilintide nor CagriSema has been approved by the FDA or any other regulatory authority as of early 2026.

Comparison With Other Metabolic Peptides

Understanding cagrilintide’s position within the broader landscape of metabolic peptides requires comparison across receptor targets, mechanisms, and published clinical outcomes. The following table summarizes key characteristics of cagrilintide and other investigational or approved metabolic peptides currently available for research.

Feature	Cagrilintide	Semaglutide	CagriSema	Retatrutide	Survodutide
Classification	Amylin analog	GLP-1 agonist	Amylin + GLP-1 combination	Triple agonist (GLP-1/GIP/GCGR)	Dual agonist (GLP-1/GCGR)
Receptor Targets	AMY1, AMY2, AMY3, CTR	GLP-1R	AMY1-3, CTR + GLP-1R	GLP-1R, GIPR, GCGR	GLP-1R, GCGR
Developer	Novo Nordisk	Novo Nordisk	Novo Nordisk	Eli Lilly	Boehringer Ingelheim
Half-Life	~7 days	~7 days	~7 days (both components)	~6 days	~6-7 days
Dosing Frequency	Once weekly	Once weekly	Once weekly	Once weekly	Once weekly
Body Weight Reduction (Phase 2)	~10-11%	~15-17%	~22-24%	~24%	~19%
Primary Satiety Mechanism	Area postrema / brainstem	Hypothalamic centers	Both brainstem + hypothalamus	Hypothalamic + energy expenditure	Hypothalamic + hepatic lipid oxidation
Regulatory Status (2026)	Phase 3 (combination)	FDA-approved	Phase 3	Phase 3	Phase 3

Several points emerge from this comparison. First, cagrilintide engages a fundamentally different receptor system than the incretin-based peptides (semaglutide, retatrutide, survodutide, mazdutide), which all target variations of the GLP-1 receptor pathway. Second, the CagriSema combination demonstrates that combining two distinct signaling pathways (amylin + GLP-1) can achieve efficacy comparable to triple receptor agonism (retatrutide), but through an entirely different mechanistic route. Third, the ~7-day half-life achieved through fatty acid acylation is remarkably consistent across all of these next-generation metabolic peptides, reflecting a shared engineering approach to extending duration of action.

Cross-trial comparisons carry inherent limitations, including differences in study populations, designs, dose-escalation protocols, and endpoints. Head-to-head trials would be required to draw definitive conclusions about relative efficacy.

Dosing Information From Published Research

The following table summarizes dosing parameters reported in published cagrilintide clinical trials. These values are derived from controlled research settings and are presented for informational purposes only.

Parameter	Cagrilintide Monotherapy	CagriSema Combination
Route of Administration	Subcutaneous injection	Subcutaneous injection (co-formulated or separate)
Dosing Frequency	Once weekly	Once weekly
Dose Range Studied	0.3 mg to 4.5 mg	Cagrilintide 2.4 mg + semaglutide 2.4 mg
Dose Escalation	Gradual titration over several weeks	Gradual titration of both components
Half-Life	~7 days (supporting once-weekly dosing)	~7 days (both components)
Trial Duration	26 weeks (Phase 2)	32-68 weeks (Phase 2/3)

Dose-escalation protocols were employed in all published trials to mitigate gastrointestinal adverse events during the initial exposure period. Starting doses were substantially lower than target maintenance doses, with step-wise increases at defined intervals. Researchers designing studies involving cagrilintide should consult the original trial protocols for specific titration schedules.

Safety Profile Observed in Research

Across published Phase 1 and Phase 2 data, the safety profile of cagrilintide has been characterized in controlled clinical trial settings. The following observations have been reported.

Gastrointestinal Effects

Consistent with the known pharmacology of amylin receptor agonism and its effects on gastric emptying, the most commonly reported adverse events have been gastrointestinal:

• Nausea — The most frequently reported event across all active treatment groups, occurring at higher rates than placebo. Incidence was dose-dependent and most pronounced during the dose-escalation phase. Most events were rated mild to moderate in severity.
• Vomiting — Reported in a subset of subjects, generally during the initial weeks of treatment and diminishing with continued dosing.
• Diarrhea and constipation — Both reported at higher rates than placebo, though generally mild.
• Decreased appetite — Observed across dose groups, consistent with the peptide’s mechanism of action on satiety signaling pathways.

These gastrointestinal effects are pharmacologically expected given cagrilintide’s mechanism of slowing gastric emptying and activating brainstem satiety circuits. The use of gradual dose escalation was observed to reduce the incidence and severity of these events in published trials.

Injection Site Reactions

Mild injection site reactions were reported in some subjects, consistent with subcutaneous peptide administration. No serious injection site events were reported in published data.

Discontinuation Rates

Discontinuation rates due to adverse events in Phase 2 trials were generally low and comparable to rates observed with other metabolic peptides in the same class. The majority of subjects who experienced gastrointestinal side effects continued treatment through the dose-escalation period.

Areas Requiring Further Investigation

• Long-term safety — Published exposure data is limited to 26-68 weeks. The Phase 3 REDEFINE program will provide longer-duration safety data essential for characterizing the chronic use profile.
• Cardiovascular safety — While no cardiovascular safety signals have been identified in published data, dedicated cardiovascular outcome data from Phase 3 trials will be important for comprehensive safety characterization.
• Combination-specific effects — The CagriSema combination involves simultaneous activation of two receptor systems, and the Phase 3 program will provide the largest dataset for evaluating whether the combination produces any adverse effects not observed with either component alone.
• Effects in special populations — Data in renally impaired, hepatically impaired, elderly, and adolescent populations remains limited or under investigation.
• Pancreatitis and gallbladder events — As with other peptides affecting gastric emptying and metabolic signaling, these events are being monitored in clinical trials.

All safety data currently available comes from controlled clinical trial settings with specific inclusion and exclusion criteria. The Phase 3 REDEFINE program, enrolling larger and more diverse populations, will substantially expand the safety database.

Summary

Cagrilintide represents a pharmacologically distinct approach to metabolic peptide research. By targeting the amylin receptor system — a signaling axis that operates through brainstem satiety circuits, gastric emptying modulation, and glucagon suppression — it engages biological pathways that are complementary to, rather than redundant with, the incretin-based mechanisms of GLP-1 and GIP receptor agonists.

Key points from the current research landscape include:

• Molecular innovation — The C18 fatty diacid acylation strategy extends cagrilintide’s half-life from approximately 13 minutes (native amylin) to approximately 7 days, enabling once-weekly dosing and representing a significant pharmacological advancement over pramlintide.
• Monotherapy efficacy — Phase 2 data demonstrated approximately 10-11% body weight reduction with cagrilintide alone, establishing the amylin pathway as a meaningful contributor to body weight regulation in clinical research.
• Combination rationale validated — CagriSema Phase 2 data showing approximately 22-24% body weight reduction supports the hypothesis that amylin and GLP-1 pathways are non-redundant and can be combined for additive or synergistic effects.
• Distinct mechanism — The primary satiety signaling through the area postrema and brainstem, rather than hypothalamic centers, distinguishes cagrilintide from all currently approved and most investigational metabolic peptides.
• Ongoing Phase 3 program — The REDEFINE trials will provide the comprehensive efficacy and safety data needed for potential regulatory submissions.

As the metabolic peptide research field continues to evolve toward multi-pathway approaches, cagrilintide and the amylin receptor system occupy a unique and increasingly important position. The distinction between brainstem-mediated and hypothalamic-mediated satiety signaling, and the demonstrated complementarity of these two systems, has implications not only for cagrilintide’s clinical development but for broader understanding of how redundant biological safeguards regulate energy balance.

Researchers interested in the broader landscape of metabolic peptides may also find the following guides relevant: retatrutide (triple GLP-1/GIP/glucagon agonist), survodutide (dual GLP-1/glucagon agonist), and mazdutide (dual GLP-1/glucagon agonist). For research-grade cagrilintide, visit the product page.

---

---

Summary of Key Research References

Study	Year	Type	Focus	Reference
Dehestani et al.	2021	Review	Amylin analogues as future obesity treatment	PMC8735818
Lau et al.	2021	Clinical Trial	Once-weekly cagrilintide dose-finding phase 2 trial	PMID 34798060
Enebo et al.	2021	Clinical Trial	Cagrilintide with semaglutide phase 1b safety and pharmacokinetics	PMID 33894838
Mathieu et al.	2023	Review	Long-acting amylin analogues for obesity management	PMID 35066542
Coskun et al.	2024	Research	Cagrilintide action through brain amylin receptors	PMC12270663
Frias et al.	2023	Review	Cagrilintide as long-acting amylin analog for obesity	PMID 36883831
Rubino et al.	2024	Review	Amylin analogs for obesity treatment without diabetes	PMID 39317404